Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug;29 Suppl 3(Suppl 3):S788-800.
doi: 10.1007/s11606-014-2895-9.

A systematic review of approaches for engaging patients for research on rare diseases

Laura P Forsythe  1 , Victoria Szydlowski, Mohammad Hassan Murad, Stanley Ip, Zhen Wang, Tarig A Elraiyah, Rachael Fleurence, David H Hickam
Affiliations

A systematic review of approaches for engaging patients for research on rare diseases

Laura P Forsythe et al. J Gen Intern Med. 2014 Aug.

Abstract

Background: Patients with rare diseases have limited access to useful information to guide treatment decisions. Engagement of patients and other stakeholders in clinical research may help to ensure that research efforts in rare diseases address relevant clinical questions and patient-centered health outcomes. Rare disease organizations may provide an effective means to facilitate patient engagement in research. However, the effectiveness of patient-engagement approaches, particularly for the study of rare diseases, has not been well studied.

Objectives: To synthesize evidence about engagement of patients and other stakeholders in research on rare diseases, including the role of rare disease organizations in facilitating patient-centered research.

Methods/research design: A systematic review and gray literature search were guided by a technical expert panel composed of patient representatives, clinicians, and researchers. English-language studies that engaged patients or other stakeholders in research on rare diseases or evaluated engagement were included. Studies were assessed on how well key research questions were answered, based on the level of detail describing engagement activities and whether outcomes from engagement were assessed.

Results: Thirty-five studies were included, although many reported minimal information on engagement. Patients and other stakeholders were most commonly engaged to identify patient-centered research agendas, to select which study outcomes were important to patients, to provide input on study design, and to identify strategies for increasing enrollment in trials. Rare disease organizations mainly helped provide access to patients and communicated research opportunities and findings. They also helped promote collaborative networks and provided financial support for research infrastructures. Although authors reported benefits of engagement and identified changes to their research processes, no empirical assessments of engagement practices and their effectiveness were found.

Conclusions: Researchers studying rare diseases can obtain patient input regarding which research questions and health outcomes to study; however, the most effective approaches to engagement have not been well defined.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study screening and selection.
Text Box 1.
Text Box 1.
Illustrative Example of a Study that Was Sufficiently Descriptive with Respect to Research Engagement
See this image and copyright information in PMC

References

    1. Andersen T. The political empowerment of rare disease patient advocates both at EU and national level. Orphanet Journal Of Rare Diseases. 2012;7(2):A33. doi: 10.1186/1750-1172-7-S2-A33. - DOI
    1. European Organization for Rare Diseases (EURORDIS). Patients’ priorities and needs for rare disease research 2014-2020. Available at: http://www.eurordis.org/sites/default/files/publications/what_how%20_are... Accessed April 30, 2014.
    1. Forsythe LP, Frank L, Walker KO, Hayes D, Levine S, Anise A, et al., editors. Patient and Clinician Views on Comparative Effectiveness Research and Engagement in Research: A Panel Discussion on PCORI Survey Results. AcademyHealth Annual Research Meeting; 2013 June 2013; Baltimore, MD.
    1. Landy DC, Brinich MA, Colten ME, Horn EJ, Terry SF, Sharp RR. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. Genet Med. 2012;14(2):223–228. doi: 10.1038/gim.0b013e3182310ba0. - DOI - PubMed
    1. Concannon TW, Meissner P, Grunbaum JA, McElwee N, Guise JM, Santa J, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. J Gen Intern Med. 2012;27(8):985–991. doi: 10.1007/s11606-012-2037-1. - DOI - PMC - PubMed

Publication types